Your institution may have rights to this item. Sign in to continue.
Title
A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-[alpha] or -[beta]: An Italian Sarcoma Group study.